Microbiologic characteristics and in vitro susceptibility to antimicrobials in a large population of patients with cardiovascular implantable electronic device infection

Journal of Cardiovascular Electrophysiology

Volumn 23, Issue 4, 2012, Pages 375-381

  Jan, Emilie ^a   Camou, Fabrice ^a   Texier Maugein, Jeannette ^a   Whinnett, Zachary ^a   Caubet, Olivier ^a   Ploux, Sylvain ^a   Pellegrin, Jean Luc ^a   Ritter, Philippe ^a   Metayer, Philippe L ^a   Roudaut, Raymond ^a   Haissaguerre, Michel ^a   Bordachar, Pierre ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

antimicrobial drugs; implantable cardioverter defibrillator; infection; pacemaker

Indexed keywords

DAPTOMYCIN; LINEZOLID; OFLOXACIN; OXACILLIN; PRISTINAMYCIN; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CARDIOVASCULAR EQUIPMENT; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DEVICE INFECTION; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; CHI-SQUARE DISTRIBUTION; DEVICE REMOVAL; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOCARDITIS, BACTERIAL; EQUIPMENT CONTAMINATION; EQUIPMENT DESIGN; FRANCE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PREDICTIVE VALUE OF TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 84860136797     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02212.x     Document Type: Article

References (22)

1. Uslan DZ, Baddour LM,: Cardiac device infections: Getting to the heart of the matter. Curr Opin Infect Dis 2006; 19: 345-348.
2. Cabell CH, Heidenreich PA, Chu VH, Moore CM, Stryjewski ME, Corey GR, Fowler VG Jr,: Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J 2004; 117: 582-586.
3. Klug D, Lacroix D, Savoye C, Goullard L, Grandmougin D, Hennequin JL, Kacet S, Lekieffre J,: Systemic infection related to endocarditis on pacemaker leads: Clinical presentation and management. Circulation 1997; 95: 2098-2107.
4. Klug D, Wallet F, Lacroix D, Marquié C, Kouakam C, Kacet S, Courcol R,: Local symptoms at the site of pacemaker implantation indicate latent systemic infection. Heart 2004; 94: 882-886.
5. Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG, Carrillo RG, Crossley GH III, Epstein LM, Friedman RA, Kennergren CE, Mitkowski P, Schaerf RH, Wazni OM,; Heart Rhythm Society; American Heart Association: Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: This document was endorsed by the American Heart Association (AHA). Heart Rhythm 2009; 6: 1085-1104.
6. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner DL, Wilson WR, Steckelberg JM, Baddour LM,: Permanent pacemaker and implantable cardioverter defibrillator infection: A population-based study. Arch Intern Med 2007; 167: 669-675.
7. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Stoner SM, Baddour LM,: Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007; 45: 166-173.
8. Tarakji KG, Chan EJ, Cantillon DJ, Doonan AL, Hu T, Schmitt S, Fraser TG, Kim A, Gordon SM, Wilkoff BL,: Cardiac implantable electronic device infections: Presentation, management, and patient outcomes. Heart Rhythm 2010; 7: 1043-1047.
9. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison MP, Lockhart PB, Masoudi MA, Okum EJ, Wilson WR, Beerman LB, Bolger AF, Estes NA III, Gewitz M, Newburger JW, Schron EB, Taubert KA,: Update on cardiovascular implantable electronic device infections and their management: A scientific statement from the American Heart Association. Circulation 2010; 121: 458-477.
10. Munoz P, Rodriguez-Creixems M, Moreno M, Marin M, Ramallo V, Bouza E,: Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007; 13: 211-215.
11. Stewart PS, Davison WM, Steenbergen JN,: Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2009; 53: 3505-3507.
12. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E,: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005; 41: 354-367.
13. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Stoner S, Baddour LM,: Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007; 49: 1851-1859.
14. Durack DT, Lukes AS, Bright DK,: New criteria for diagnosis of infective endocarditis: Utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96: 200-209.
15. Bekeris LG, Tworek JA, Walsh MK, Valenstein PN,: Trends in blood culture contamination: A College of American Pathologists Q-tracks study of 356 institutions. Arch Pathol Lab Med 2005; 129: 1222-1225.
16. Golzio PG, Vinci M, Anselmino M, Comoglio C, Rinaldi M, Trevi GP, Bongiorni MG,: Accuracy of swabs, tissue specimens, and lead samples in diagnosis of cardiac rhythm management device infections. Pacing Clin Electrophysiol 2009; 32: 76-80.
17. Klug D, Wallet F, Lacroix D, Marquie C, Kouakam C, Kacet S, Courcol R,: Local symptoms at the site of pacemaker implantation indicate latent systemic infection. Heart 2004; 90: 882-886.
18. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HP, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt SM, Tice A, Cosgrove SE,: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665.
19. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C,: Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48: 203-212.
20. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ,: Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-2726.
21. Bressler AM, Zimmer SM, Gilmore JL, Somani J,: Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4: 528-531.
22. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL,: Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50: 1568-1574.